KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $229.2 million.

  • Nektar Therapeutics' Short-term Investments rose 689.88% to $229.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.2 million, marking a year-over-year increase of 689.88%. This contributed to the annual value of $211.0 million for FY2024, which is 2137.78% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Short-term Investments of $229.2 million as of Q3 2025, which was up 689.88% from $132.9 million recorded in Q2 2025.
  • Nektar Therapeutics' Short-term Investments' 5-year high stood at $887.2 million during Q1 2021, with a 5-year trough of $132.9 million in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' median Short-term Investments value was $358.7 million (recorded in 2023), while the average stood at $425.0 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Short-term Investments crashed by 4918.14% in 2022, and later soared by 689.88% in 2025.
  • Nektar Therapeutics' Short-term Investments (Quarter) stood at $708.7 million in 2021, then crashed by 41.2% to $416.8 million in 2022, then tumbled by 35.61% to $268.3 million in 2023, then decreased by 21.38% to $211.0 million in 2024, then rose by 8.63% to $229.2 million in 2025.
  • Its Short-term Investments was $229.2 million in Q3 2025, compared to $132.9 million in Q2 2025 and $179.7 million in Q1 2025.